Highlights

  • On 13 July 2026 Orthocell reported record quarterly Revenue of $3.8 million for the June quarter, a 20 per cent lift on the March quarter and.
  • The trajectory of the Top Line is the headline metric for a company at this stage.
  • The clearest potential catalysts are commercial.
  • The central risk is execution in a foreign market: building a US sales force and clinical adoption is expensive and slow, and cash burn could outrun.

On 13 July 2026 Orthocell reported record quarterly revenue of $3.8 million for the June quarter, a 20 per cent lift on the March quarter and about 36 per cent higher than the prior corresponding period, capping what the company described as a record full-year FY26 revenue result. Management followed with a results webinar in mid-July featuring chair John Van Der Wielen, chief executive Paul Anderson, chief financial officer Jim Piper and US sales head John Walker. Earlier in 2026 Orthocell secured approval to Supply Remplir into the United States Department of Defense hospital network, reported across dozens of DoD locations, broadening the addressable base beyond private practice.

Latest company developments

On 13 July 2026 Orthocell reported record quarterly revenue of $3.8 million for the June quarter, a 20 per cent lift on the March quarter and about 36 per cent higher than the prior corresponding period, capping what the company described as a record full-year FY26 revenue result. Management followed with a results webinar in mid-July featuring chair John Van Der Wielen, chief executive Paul Anderson, chief financial officer Jim Piper and US sales head John Walker. Earlier in 2026 Orthocell secured approval to supply Remplir into the United States Department of Defense hospital network, reported across dozens of DoD locations, broadening the addressable base beyond private practice. Through August the company leaned into investor outreach, presenting at the Canaccord Genuity Growth Conference in Boston on 12 August and publishing profiles of its US Marketing and sales leadership. Orthocell has also flagged its ambition to progress Remplir toward broader US regulatory milestones, positioning the collagen nerve wrap for wider surgical use beyond the initial channels.

Financial and operating picture

The trajectory of the top line is the headline metric for a company at this stage. Trailing revenue running near $9 million and growing at more than 20 per cent, together with a June-quarter record of $3.8 million, shows genuine commercial traction rather than a purely pre-revenue concept. The counterweight is that Orthocell remains loss-making, with negative earnings per share, and net tangible backing is modest at around 15 cents a share. The September 2025 raising put cash on the Balance Sheet to fund the US build-out, but every quarter of heavy sales, marketing and headcount spend is a call on that capital. No Dividend is paid, which is appropriate for a growth-stage medical device Business reinvesting to capture a market. The Investment case therefore hinges on operating leverage: whether the record quarterly sales convert, over time, into a path to breakeven before further Capital is required.

What to watch next

The clearest potential catalysts are commercial. Continued quarter-on-quarter revenue growth from Remplir in the US, and evidence that the Department of Defense hospital access is translating into repeat orders, would support the thesis that Orthocell is scaling. Progress on broader US regulatory pathways for its nerve-repair and soft-tissue products could expand the opportunity. Positive surgeon adoption data, new distribution agreements or a maiden move toward operating profitability would each be meaningful. Investor engagement of the kind seen at the Boston conference can also widen the Shareholder base over time. Conversely, the market will want the next quarterly cash-flow report to show the spending is disciplined relative to the revenue it is generating.

Risks

The central risk is execution in a foreign market: building a US sales force and clinical adoption is expensive and slow, and cash burn could outrun revenue, raising the prospect of further capital raisings that dilute existing holders. Adoption of a novel nerve-repair product depends on surgeon behaviour and, ultimately, on reimbursement and clinical outcomes. Regulatory timelines for expanded US indications are outside the company's control and can slip. Competition from established wound-care and surgical suppliers is a persistent structural threat, and any Manufacturing or supply constraint would bite a company still small in scale.

Outlook

Orthocell offers a relatively rare combination for a small-cap Australian biotech: an approved product, record and growing revenue, and a defined US commercialisation runway. The upside case rests on that revenue curve steepening as the Remplir rollout matures and the Department of Defense channel opens up. The downside case is equally clear: the shares have already fallen a long way from the 2025 Placement price, the business still loses money, and further funding cannot be ruled out if the burn stays high. The day's.